Servier Acquires Promising Treatment for Fragile X Syndrome
AI-Generated Summary
Servier has acquired KER-0193, a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder, from Kaerus Bioscience. The orally bioavailable small molecule has successfully completed Phase 1 clinical trials and received Orphan Drug and Rare Pediatric Drug Designations from the U.S. FDA. This acquisition aligns with Servier's 2030 strategy to expand its neurology franchise, focusing on rare indications with high unmet medical needs.
In a nutshell
This acquisition signals a significant step in the pharmaceutical industry's efforts to address rare neurological conditions like Fragile X syndrome, which currently lacks approved treatments. Servier's strategic investment in this area highlights the increasing focus on developing targeted therapies for underserved patient populations, offering potential new hope for individuals and families affected by FXS.
Source: Europa Press
